Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 9/20 | 0.49 |
| ▸ | CTSL | P07711 | 8/20 | 0.49 |
| ▸ | CTSS | P25774 | 8/20 | 0.49 |
| ▸ | CTSB | P07858 | 7/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ELANE | P08246 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14288626 | 0.85 | CTRB1 (0.58) | CTRB1CTSKCTSLCTSSCTSB | |
| SCHEMBL553905 | 0.85 | CTRB1 (0.61) | CTRB1SYKATM | |
| SCHEMBL553906 | 0.85 | CTRB1 (0.61) | CTRB1SYKATM | |
| SCHEMBL264008 | 0.85 | CTRB1 (0.61) | CTRB1SYKATM | |
| SCHEMBL4829896 | 0.84 | CTRB1 (0.68) | CTRB1CTSKCTSLCTSSCTSB | |
| SCHEMBL7986494 | 0.84 | CTRB1 (0.54) | CTRB1CTSKCTSLCTSSCTSB | |
| SCHEMBL10058366 | 0.84 | CASP1 (0.49) | CTRB1CTSKCTSLCTSSCTSB | |
| SCHEMBL79250 | 0.84 | CTRB1 (0.57) | CTRB1CTSKCTSLCTSSCTSB | |
| SCHEMBL555191 | 0.84 | CTRB1 (0.57) | CTRB1CTSKCTSLCTSSCTSB | |
| SCHEMBL555192 | 0.84 | CTRB1 (0.57) | CTRB1CTSKCTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094672-B1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH INC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8168645-B2 | Arylsulfonamide compounds | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | ABBOTT LABORATORIES | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035879-A1 | N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS | BAX, BCL2, BAD | CTRB1 1229/4885CTSK 2195/4885CTSL 774/4885 |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | BCL2A1, BCL2, BAX | CTRB1 142/4885CTSK 1449/4885CTSL 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.